Anaptysbio, Inc

  • Moat Score
  • Market Cap $629.79M
  • PE -4
  • Debt -
  • Cash $98.64M
  • EV -
  • FCF -$109.15M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$140.62M
EBIT-$100.29M
ROE-413%
ROA-24%
FCF-$109.15M
Equity$34.02M
Growth Stability1
PE-4.48
PB18.51
P/FCF-5.77
P/S5.63
Price/Cash0.16
Net Margins-142%
Op. Margins-90%
Sales Growth YoY287%
Sales Growth QoQ-36%
Sales CAGR23%
Equity CAGR-18%
Earnings Growth YoY-10%
Earnings Growth QoQ81%
Sales CAGR 5Y-2%
Equity CAGR 5Y-44%
Earnings CAGR 3Y142%
Sales CAGR 3Y142%
Equity CAGR 3Y-58%
Market Cap$629.79M
Revenue$111.87M
Assets$422.05M
Cash$98.64M
Shares Outstanding30.39M
Moat Score1%
Working Capital319.08M
Current Ratio8.25
Shares Growth 3y1%
Equity Growth QoQ-52%
Equity Growth YoY-29%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.

SEC Filings

Direct access to Anaptysbio, Inc (ANAB) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2025
    • 10-Q Mar 31
  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Anaptysbio, Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Anaptysbio, Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Anaptysbio, Inc Discounted Cash Flow

Fully customizable DCF calculator online for Anaptysbio, Inc.

= -$1.1B
012345678910TV
fcf-$109M-$109M-$109M-$109M-$109M-$109M-$109M-$109M-$109M-$109M-$109M-$1.1B
DCF-$99M-$90M-$82M-$75M-$68M-$62M-$56M-$51M-$46M-$42M-$421M
Value-$1.1B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins-31%-26%-301%-1K%-1K%-27%-91%-1K%-954%-159%-142%
ROA--5%-9%-12%-22%-5%-9%-19%-36%-24%-24%
ROE-11%-10%-13%-24%-5%-16%-49%-186%-205%-413%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF--0-0.35-0.15-0.02-0-----
Debt over Equity--00.020.0200-----
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth--5%-40%-50%60%838%-16%-84%67%432%-2%
Earnings YoY growth--21%606%105%58%-80%190%123%27%-11%-
Equity YoY growth-9%-904%58%-17%-2%-10%-26%-66%-20%-44%
FCF YoY growth--9%117%151%42%-79%221%56%64%12%-